AlphAIAlphAI — Financial news for AI agents
mugglehead.comOCT 92 min read$JNJ

Johnson & Johnson reports at least 72% PASI 90

Johnson & Johnson (JNJ) reported that its oral psoriasis drug ICOTYDE maintained at least 72% PASI 90 response rates through week 112 in the Phase 3 ICONIC-LEAD trial. JNJ shares rose 0.40% to $257.50. Alumis (ALMS) is also developing a psoriasis drug, envudeucitinib, with a planned U.S. application in Q4 2026.

Original reporting
mugglehead.com
Published Oct 9, 2026, 1:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 2:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JNJ
Bullish
high confidence
Mentioned
$JNJ · $ALMS
Relevance
8/10
AlphAI data visualization · based on mugglehead.com
Decision brief

The 30-second read

$JNJBullishMed
01

Why it matters

Both companies receive positive clinical readouts, which could influence near‑term stock moves and sector sentiment.

02

Market read

New clinical data for two dermatology candidates may drive modest price reactions in JNJ and ALMS and lift biotech sentiment.

03

What to watch

Potential safety signals not disclosed; reimbursement and market adoption uncertainties could dampen impact.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

The article reports first‑time two‑year efficacy results for J&J's oral psoriasis drug ICOTYDE and compares them with Alumis' Phase 3 data, noting upcoming FDA filing timelines.

Company-level read

Ticker impact

$JNJBullishHigh confidence
Context

Johnson & Johnson released two-year Phase 3 ICONIC-LEAD trial data showing ≥72% PASI 90 response, a first report of long-term efficacy for ICOTYDE.

Expected impact

likely modest upside as market prices in the durability data

Evidence & confidence

First disclosure of two‑year efficacy, no new safety signals, and a small pre‑market price rise indicate positive sentiment.

$ALMSBullishMedium confidence
Context

Alumis Inc. disclosed its own Phase 3 psoriasis data and a planned Q4 2026 FDA filing, presented alongside JNJ's results.

Expected impact

potential modest upside as investors anticipate filing momentum

Evidence & confidence

Data are new but less impactful than JNJ's; market may price in upcoming regulatory timeline.

Market effects

Sector

Biotech sector may see broader uplift as long‑term psoriasis data emerge, supporting other oral immunology programs.

Regional

U.S. biotech equities could benefit modestly; no clear regional bias.

Global

Limited to investors tracking dermatology pipelines and oral IL‑23/TYK2 inhibitors.

Counterpoint

What could challenge this read

Durability data may not translate into commercial success if pricing or competition from biologics remains strong.

Key entities

  • company
    Johnson & Johnson

    US‑listed healthcare conglomerate reporting long‑term psoriasis trial data.

  • company
    Alumis Inc.

    Biotech firm with oral TYK2 inhibitor envudeucitinib, reporting Phase 3 data and filing plans.

Read at source← All news

StoryJohnson & Johnson reports two‑year Phase 3 results for ICOTYDE in plaque psoriasis

Also covered by

3 outlets

Related articles

OCT 9
$JNJMed

Johnson & Johnson Announces New Two-Year Results from Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE in Adults and Adolescents with Moderate-To-Severe Plaque Psoriasis

Johnson & Johnson presented two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE® in moderate-to-severe plaque psoriasis. Data showed high skin clearance rates and sustained symptom improvement with no new safety signals. 72% of patients achieved PASI 90, and 70% achieved IGA 0/1. The study included 684 participants, with 66 adolescents. ICOTYDE is approved in the U.S., Europe, Japan, and China for psoriasis treatment.

marketscreener.com2 min
OCT 9
$BSXMed

Boston sues J&J subsidiary over alleged patent infringement for cardiology device

Boston Scientific sued Johnson & Johnson subsidiary Atraverse Medical, alleging patent infringement by its Hotwire device. Boston claims Atraverse knew its actions infringed Patent '955 and seeks damages and an injunction. J&J acquired Atraverse in 2026. The electrophysiology ablation catheter market is growing at 11.1% CAGR, with J&J's Biosense Webster leading at 43.1% market share in 2025.

finance.yahoo.com2 min
OCT 9
$ALMSMedAI 8/10

Alumis Shares New Phase 3 Psoriasis Data For Envudeucitinib; Stock Up

Alumis Inc. (ALMS) reported Phase 3 data showing envudeucitinib improved scalp psoriasis, itching, and quality of life in patients. Key findings: 54% achieved complete skin clearance, 80% maintained clear scalp skin, and 40% reported complete itch resolution. The drug was well tolerated. ALMS stock rose 2.95% on Thursday and is up 4.02% in premarket trading.

rttnews.com1 min
OCT 9
$JNJMed

Johnson & Johnson Reports Sustained Two-Year ICOTYDE Results In Plaque Psoriasis

Johnson & Johnson (JNJ) reported two-year results from its Phase 3 ICONIC-LEAD study of ICOTYDE for plaque psoriasis, showing sustained skin clearance and symptom improvements. At Week 112, 72% of patients achieved PASI 90, 70% had clear/almost clear skin, and 44% had complete clearance. Safety findings were consistent with the drug's profile. JNJ is also studying ICOTYDE for other conditions. JNJ closed at $256.48, down 0.76%, and was down 0.15% in premarket trading.

rttnews.com2 min